NeuroSense Therapeutics Ltd., a foreign private issuer, has successfully completed the in-life phase of a nine-month non-rodent toxicity study as of September 2024. The study, initiated in November 2023, was conducted in line with discussions with the U.S. Food and Drug Administration (FDA) regarding trial design. The positive outcomes of the study support the regulatory strategy of NeuroSense Therapeutics and affirm the long-term safety profile of its drug candidate, PrimeC. The completion of this phase is a significant milestone for the company and has been documented in the Report on Form 6-K, which is also incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.

NeuroSense Therapeutics Ltd., a foreign private issuer, has successfully completed the in-life phase of a nine-month non-rodent toxicity study as of September 2024. The study, initiated in November 2023, was conducted in line with discussions with the U.S. Food and Drug Administration (FDA) regarding trial design. The positive outcomes of the study support the regulatory strategy of NeuroSense Therapeutics and affirm the long-term safety profile of its drug candidate, PrimeC. The completion of this phase is a significant milestone for the company and has been documented in the Report on Form 6-K, which is also incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.